Design of Topical Moxifloxacin Mucoadhesive Nanoemulsion for the Management of Ocular Bacterial Infections

Ocular bacterial infections can lead to serious visual disability without proper treatment. Moxifloxacin (MOX) has been approved by the US Food and Drug Administration as a monotherapy for ocular bacterial infections and is available commercially as an ophthalmic solution (0.5% <i>w</i>/...

وصف كامل

التفاصيل البيبلوغرافية
الحاوية / القاعدة:Pharmaceutics
المؤلفون الرئيسيون: Ahmed Adel Ali Youssef, Ruchi Thakkar, Samir Senapati, Poorva H. Joshi, Narendar Dudhipala, Soumyajit Majumdar
التنسيق: مقال
اللغة:الإنجليزية
منشور في: MDPI AG 2022-06-01
الموضوعات:
ocular bacterial infections
moxifloxacin
nanoemulsion
transcorneal
mucoadhesive agent
ex vivo
الوصول للمادة أونلاين:https://www.mdpi.com/1999-4923/14/6/1246

الانترنت

https://www.mdpi.com/1999-4923/14/6/1246

مواد مشابهة